<div id="readability-page-1"><div><p><span>Coyne Terrance P Chief Financial Officer of Royalty Pharma PLC [RPRX] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/1/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Planned Sale(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>69,582</span></td></tr><tr><td><span>Price</span></td><td><span>$39.87</span></td></tr><tr><td><span>Value</span></td><td><span>$2,773,956</span></td></tr></tbody></table></div><p><span>Ending Holdings: 690,142 (1,500 - Direct, 688,642 - Indirect)</span></p><ul><li><span>(1)</span></li><li><span>Executed pursuant to a prearranged trading plan (10b5-1).</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

RPRX

<p>CFO Coyne Terrance P of Royalty Pharma PLC sold 69,582 shares worth $2.8 million, as disclosed in a Form 4 filed with the SEC. The transaction was executed under a prearranged trading plan (10b5-1). Coyne's ending holdings are 690,142 shares. The Washington Service provides insider trading analysis and data services.</p>

CFO Coyne Sells 69,582 ($2.8M) Of Royalty Pharma PLC [RPRX]